<DOC>
	<DOC>NCT00674063</DOC>
	<brief_summary>Comparison of two dosing regimens of Alefacept in subjects weighing between 100kg and 150kg with moderate to severe Chronic Plaque Psoriasis</brief_summary>
	<brief_title>A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Alefacept</mesh_term>
	<criteria>Body weight between 100kg and 150kg Diagnosis of Chronic Plaque Psoriasis with Body Surface Area (BSA) involvement of ≥ 10% Candidate for phototherapy or systemic therapy for Psoriasis CD4 + T lymphocyte counts &gt; lower limit of normal Clinically significant abnormal hematology values or blood chemistry values ALT or AST value of ≥ 3x the upper limit of normal Other types of Psoriasis Serious infection within 3 months prior to 1st dose of study drug Antibody positive for HIV History of malignancy History of severe allergic or anaphylactic reactions History of any clinically significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal and/or other major disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Chronic Plaque Psoriasis</keyword>
	<keyword>Alefacept</keyword>
</DOC>